A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction

Trial Profile

A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs NEOD 001 (Primary)
  • Indications Amyloid light-chain amyloidosis
  • Focus Registrational; Therapeutic Use
  • Acronyms PRONTO
  • Sponsors Prothena
  • Most Recent Events

    • 08 Aug 2017 According to a Prothena media release, top-line results from this trial (n = 129) are expected in the second quarter of 2018.
    • 30 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 05 Jul 2016 According to Prothena Corporation media release, this study was designed to align with feedback from the European Medicines Agency (EMA) related to The VITAL Amyloidosis Study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top